| Species |
Human |
| Protein Construction |
| hFc |
CTGF/CCN2 (Gln27-Ala349)
Accession # Q5M8T4 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized CTGF/CCN2 hFc Chimera, Human at 0.2μg/ml (100μl/Well) on the plate can bind Biotinylated AntiCTGF Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
61.77 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 50-55 kDa and 62-72 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Connective tissue growth factor (CTGF) is a member of the CCN matricellular protein family, consisting of four domains, that regulates the signaling of other growth factors and promotes kidney fibrosis.CTGF can simultaneously interact with several factors with its four domains. The microenvironment differs depending on the types of cells and tissues and differentiation stages of these cells. |
| Synonyms |
IGFBP8; IBP-8; CCN2; NOV2; HCS24; CTGF; CTGRP; Fisp12; MGC102839 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
